19 results about "PSMA Antibody" patented technology

The invention relates to an anti-PSMA antibody-drug conjugate and a medical application thereof. Specifically, the anti-PSMA antibody-drug conjugate is shown as a general formula Pc-L-Y-D, Pc is an anti-PSMA antibody or an antigen binding fragment thereof, and L, Y and n are defined as in the specification.

The present invention relates to antibodies that bind to prostate-specific membrane antigen (PSMA).

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind PSMA, as well as STING agonist linker-drug conjugates and preparation thereof, are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and / or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

The present invention relates to anti-adhesin 2 antibodies or antigen-binding fragments thereof, anti-PSMA antibodies or antigen-binding fragments thereof, bispecific antibody constructs that bind to adhesin 2 and PSMA, and antibody-drug conjugates comprising such antibodies. The invention also relates to the use of said antibody-drug conjugate for the treatment of cancer.

The present disclosure relates to antibody conjugates comprising an antibody that specifically binds to a PSMA protein conjugated to exatecan, and related therapeutic uses.

Disclosed are antibodies, antigen binding fragments and conjugates thereof (e.g., antibody-drug conjugates) that bind to PSMA, as well as STING agonist linker-drug conjugates and their preparation. The disclosure further relates to methods and compositions for treating, for example, cancer by administering the compositions provided herein.

Provided herein are novel anti-CD28 x anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28 x anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-PSMA antibodies) for the treatment of prostate cancers.

The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind PSMA, as well as STING agonist linker-drug conjugates and preparation thereof, are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

The present disclosure provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. In some embodiments, the antibodies of the disclosure bind human PSMA with high affinity and bind CD3 to induce proliferation of human T cells. The disclosure includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of tumor cells expressing PSMA. In some embodiments, the present disclosure provides bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human CD3 and a second antigen binding molecule that specifically binds human PSMA. In some embodiments, the bispecific antigen binding molecules of the present disclosure are capable of inhibiting the growth of prostate tumors expressing PSMA.The antibodies and bispecific antigen binding molecules of the disclosure are useful for the treatment of diseases and disorders where a targeted, upregulated or induced immune response is desirable and / or therapeutically advantageous. For example, the antibodies of the disclosure are useful for the treatment of various cancers.

The application discloses an engineered anti-PSMA-TAT@celinexor exosome for treating castration-resistant prostate cancer and a preparation method and application thereof. The exosome is constructed by gene engineering and chemical modification technology, and an anti-PSMA antibody fragment with prostate-specific membrane antigen targeting function and a cell-penetrating peptide TAT are co-displayed on the surface of the exosome, and an anticancer drug celinexor is efficiently loaded, so that a novel targeted drug delivery system is constructed. The system realizes the enrichment of the exosome in the prostate cancer tissue site by using anti-PSMA, and further realizes the double precise targeting from the tissue to the cell and then to the nucleus by the aid of the TAT peptide to promote the drug to penetrate the cell membrane and further target the nucleus. The strategy not only significantly enhances the accumulation and efficacy of celinexor in the nucleus of the prostate cancer, but also effectively reduces the toxic side effects of celinexor on normal tissues through the natural biocompatibility and targeted delivery characteristics of the exosome, thereby improving the treatment safety.

Disclosed herein are antibodies or antigen-binding fragments thereof, polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates that bind to prostate-specific membrane antigen (PSMA), and methods of using the same to treat cancer.

The present invention relates to compositions comprising 225Ac labeled anti-PSMA antibody conjugate and the methods of making and using regarding the same. The compositions of the present invention are useful for treating cancer including prostate cancer.

The present invention relates to prostate-specific membrane antigen antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates (ADCs). The present invention provides a method for treating a subject with an anti-PSMA ADC to inhibit, prevent, or treat a PSMA-related disease or cancer, including prostate cancer. The present disclosure also provides pharmaceutical compositions containing an anti-PSMA ADC suitable for administration to a human subject.

The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.

The present application relates to an anti-PSMA antibody-drug conjugate and the use thereof. Specifically provided are an antibody-drug conjugate as shown in formula (I) or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Ab-(L-D)a Formula (I).

The present invention relates to: anti-PSMA antibodies or antigen-binding fragments thereof; nucleic acids encoding same; recombinant expression vectors comprising the nucleic acids; host cells transfected with the recombinant expression vectors; methods for preparing the antibodies or antigen-binding fragments thereof; chimeric receptors (CARs) comprising the antibodies or antigen-binding fragments thereof; immune cell therapeutic agents comprising the chimeric receptors; antibody-drug conjugates (ADC) having the antibody or antigen-binding fragment thereof conjugated to a drug; compositions comprising the antibodies or antigen-binding fragments thereof, for diagnosing, preventing, or treating cancer; methods for diagnosing, preventing, or treating cancer; and uses thereof. The anti-PSMA antibodies or antigen-binding fragments thereof, according to the present invention, exhibit superior binding affinity compared to conventional anti-PSMA antibodies, and can be usefully employed in diagnosing, preventing, or treating target tumors or cancers.